(1) Background: Breast cancer is the most common cancer among women worldwide, with more than 2 million new cases each year, and is the leading cause of cancer death in women. Triple-negative breast cancer (TNBC) is characterized by high aggressiveness, absence of hormone receptors, and variable response to immunotherapy, posing a major therapeutic challenge, and is an aggressive subtype characterized by the lack of hormone receptors and HER2, limiting targeted therapy options. Despite advances in immunotherapy, such as PD-1/PD-L1 inhibitors, frequent resistance persists due to an immunosuppressive tumor microenvironment (TME). Key among these mechanisms is the increased infiltration of regulatory T cells (Tregs), which suppress antitumor immunity. This study investigates the molecular signatures associated with this Treg-dominant infiltration in TNBC and their prognostic impact, aiming to identify novel therapeutic targets. (2) Methods: Bioinformatics analyses on TCGA-TNBC transcriptomic data to assess immune infiltration, identify genes associated with Treg accumulation, reduced CD8+ effector T cells, and immune checkpoint expression, and correlate these signatures with prognosis. (3) Results: A panel of overexpressed genes is strongly correlated with increased infiltration of immunosuppressive cells, a reduction in CD8+ T cells, and elevated immune checkpoints, contributing to an unfavorable tumor microenvironment and a poor prognosis. (4) Conclusions: These candidate genes represent potential biomarkers of immune resistance and therapeutic targets to restore antitumor immunity in TNBC.
Previous Article in event
Previous Article in session
Next Article in event
Next Article in session
Exploration of genes identified in antitumor resistance in triple-negative breast
Published:
05 June 2026
by MDPI
in The 5th International Electronic Conference on Cancers
session Novel Methods and Technologies for Research and Treatment
Abstract:
Keywords: Triple-negative breast cancer, immunotherapy, immune infiltration, TCGA, biomarkers.
